Evidence-Based Development and Rationale for Once-Daily Rivaroxaban Dosing Regimens Across Multiple Indications

BACKGROUND: Rivaroxaban, a direct factor Xa inhibitor, has been developed to meet clinical needs in a broad range of indications in adults: prevention of venous thromboembolism after elective hip or knee replacement surgery, treatment and secondary prevention of venous thromboembolism, prevention of...

Descripción completa

Detalles Bibliográficos
Autores principales: Kubitza, Dagmar, Berkowitz, Scott D., Misselwitz, Frank
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2016
Materias:
Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4888194/
https://www.ncbi.nlm.nih.gov/pubmed/26893445
http://dx.doi.org/10.1177/1076029616631427

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4888194/
https://www.ncbi.nlm.nih.gov/pubmed/26893445
http://dx.doi.org/10.1177/1076029616631427

Ejemplares similares